Does Pediatrix (MD) Joining Russell Defensive Indexes Recast Its Profile as a Value-Safe Haven?
Pediatrix Medical Group (NYSE: MD) was recently added to the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, a move that could broaden its investor base and trading liquidity. While this inclusion suggests a perception of the company as a defensive healthcare asset, its investment narrative still faces challenges from reimbursement pressures, labor costs, and portfolio restructuring. The company's Q1 2026 earnings showed improvements, but underlying risks like future reimbursement changes remain pertinent for investors to consider, despite the new "defensive" label.
Pediatrix Medical Group stock hits 52-week high at 25.02 USD
Pediatrix Medical Group Inc. (MD) has reached a new 52-week high of $25.02, reflecting a 74.11% increase over the past year. The company, with a $2 billion market cap and a P/E ratio of 12.03, is considered undervalued by InvestingPro analysis, which also notes upward earnings revisions by four analysts. This strong performance follows the company's Q1 2026 financial results, where EPS of $0.44 and revenue of $476 million both surpassed analyst expectations.
ETFs Investing in Pediatrix Medical Group, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Pediatrix Medical Group, Inc. (MD). The funds are sorted by market value and include details such as asset manager, management style, expense ratio, and 3-year total return. The ETFs predominantly focus on small-cap equities, with some also covering health care and extended market segments.
Pediatrix Medical Group, Inc.(NYSE: MD) added to Russell 2000 Defensive Index
Pediatrix Medical Group, Inc. (NYSE: MD) has been added to the Russell 2000 Defensive Index. This news follows several recent updates for the company, including UBS adjusting its price target and the release of their Q1 2026 earnings report, which showed increased adjusted earnings and revenue. Pediatrix Medical Group is a major provider of physician services, specializing in newborn, maternal-fetal, and other pediatric subspecialty care.
Pediatrix Medical Group, Inc.(NYSE: MD) added to Russell 2000 Value-Defensive Index
Pediatrix Medical Group, Inc. (NYSE: MD) has been added to the Russell 2000 Value-Defensive Index. This announcement highlights the company's inclusion in a significant market index, reflecting its established presence in the healthcare sector. The article also provides recent news and financial data related to Pediatrix Medical Group, including analyst ratings and earnings reports.
Enterprise value to EBITDA forward of Pediatrix Medical Group, Inc. – NYSE:MD
This article provides financial data specifically focusing on the "Enterprise value to EBITDA forward" for Pediatrix Medical Group, Inc. (NYSE: MD). The content appears to be a stub or a data point from a financial platform like TradingView, indicating no available value or change for the specified metric within the given period.
Is Ongoing Sales Weakness and Softer Returns Reshaping the Investment Case For Pediatrix (MD)?
Pediatrix Medical Group (MD) has reported two consecutive years of sales decline, with current forecasts expecting flat revenue and weakening returns on capital from recent investments. This trend raises concerns about the company's resource allocation and could impact its investment narrative. Investors are advised to consider the risks associated with portfolio changes, softer demand, and potential pushback on hospital administration fees, despite an analyst outlook projecting modest revenue and earnings growth by 2029.
Pediatrix Medical Group, Inc. Actuals & Estimates (NYSE:MD)
This article provides key financial data and analyst estimates for Pediatrix Medical Group, Inc. (NYSE:MD). It covers the company's stock performance, market capitalization, earnings, revenue, and future outlook based on analyst forecasts, as well as general information for potential investors.
MD Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pediatrix Medical Group, Inc. (MD) stock, including current price, historical performance, and analyst price targets. It details recent earnings, revenue, and other financial metrics, noting that the stock has a "strong buy" rating according to technical analysis.
Form 4 Pediatrix Medical Group Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Pediatrix Medical Group Inc. on June 24. It provides the company's stock symbol (MD) and its percentage change, along with market data for various indices, commodities, bonds, and shares. The content is primarily a data dump from Investing.com, typical of automated financial news releases.
Price to earnings forward of Pediatrix Medical Group, Inc. – NYSE:MD
This article provides the "Price to earnings forward" value for Pediatrix Medical Group, Inc. (NYSE: MD), a company in the Health Services sector. It states that the market is closed with no trades recorded for this specific financial metric. The article is primarily a data point from TradingView, further referencing market and financial data providers.
Form 4 Pediatrix Medical Group Inc For: 24 June By Investing.com
This article reports on the filing of Form 4 for Pediatrix Medical Group Inc., specifically for June 24. The brief piece includes the company's stock symbol MD and indicates a 2.36% increase in its stock price.
Form 4 Pediatrix Medical Group Inc For: 24 June By Investing.com
This article announces the filing of Form 4 for Pediatrix Medical Group Inc. on June 24. It appears to be an automated notification from Investing.com about a regulatory filing, providing minimal content beyond the announcement itself. The article also includes various market data and other news headlines.
Form 4 Pediatrix Medical Group Inc For: 24 June By Investing.com
This article reports on the filing of Form 4 for Pediatrix Medical Group Inc (MD) for June 24, 2026. The brief announcement provides direct access to the filing, which details insider transactions or beneficial ownership changes. It includes the stock symbol MD and mentions that the information is provided by Investing.com, sourced from Reuters.
Form 4 Pediatrix Medical Group Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Pediatrix Medical Group Inc. on June 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of securities by a company's directors, officers, or any beneficial owner of more than 10% of a class of the company's equity securities. The article itself is very brief, only stating the filing and company, alongside general market data.
Pediatrix (MD) EVP and General Counsel David Haddock submits initial Form 3
David Haddock, EVP, General Counsel, and Corporate Secretary of Pediatrix Medical Group, Inc. (MD), has filed an initial Form 3 with the SEC. This filing serves as a baseline disclosure of his status as a reporting officer and indicates no beneficial ownership of securities or derivative positions. The Form 3 confirms there were no transactions, purchases, or sales of shares by Haddock at the time of this initial report.
[Form 4] Pediatrix Medical Group, Inc. Insider Trading Activity
David Haddock, EVP of Pediatrix Medical Group, reported insider trading activity detailing the acquisition of 20,036 shares of common stock as restricted shares and 51,000 Performance Share Units (PSUs). The restricted shares vest in increments over three years, while the PSUs vest after three years contingent on both service and stock performance conditions, specifically stock prices reaching 115%, 125%, and 135% of $22.66. These transactions reflect equity awards and incentive compensation for Haddock.
Pediatrix Medical Group Inc (MD) Institutional Confidence
The article provides an overview of Pediatrix Medical Group Inc.'s (MD) institutional confidence score, which stands at 10.00, ranking 1st in its industry. It highlights that institutional shareholding has increased by nearly 20% quarter-over-quarter, with James Simons being a major shareholder. The article also lists major institutional shareholders and their changes in holdings.
Pediatrix Medical Group (MD) Stock Price, News & Analysis $MD
Pediatrix Medical Group (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal, and pediatric subspecialty care. The company currently has a "Hold" consensus rating from analysts, with a price target of $22.50, suggesting a potential 7.2% downside from its current trading price of $24.24. Insider selling has recently outweighed insider buying, with $855,665.00 in sales and no purchases in the last three months, though institutional ownership is high at 97.71%.
Pediatrix Medical Group Stock - Long-term strategy and business model in focus
This article focuses on Pediatrix Medical Group (MD), a physician-services provider specializing in neonatal and maternal-fetal care. It highlights the company's long-term strategy, business model emphasizing partnerships with hospitals for recurring revenue, and its efforts in deleveraging and simplifying operations. The piece also details where the stock trades and key company information.
Pediatrix Medical Group Stock - Weekly move and sector check after quiet news flow
Pediatrix Medical Group (MD) stock saw a modest gain this week with quiet news flow, broadly tracking the US healthcare services sector. The company, which provides physician services in neonatal and maternal-fetal care, is characterized as a defensive healthcare exposure. Its market capitalization is slightly over $2.0 billion, and shares are currently trading around $23.60 on the NYSE.
Pediatrix Medical Group Inc (MD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pediatrix Medical Group Inc (MD), detailing its current price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. The analysis suggests suitability for range-bound swing trading, with a current "Buy" signal based on moving averages. It also includes FAQs explaining technical ratings and moving averages.
Pediatrix Medical Group Inc (MD) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Pediatrix Medical Group Inc (MD), highlighting its current valuation score and P/E ratio. The company currently has a valuation score of 8.52, ranking 38th in its industry, and a P/E ratio of 11.31, which is significantly below its recent high. The report notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pediatrix Medical Group Inc (MD) Earnings Forecast: Future EPS & Revenue Growth Estimates
Pediatrix Medical Group Inc (MD) has an earnings forecast score of 7.14, ranking 46th in the Healthcare Providers & Services industry, with an average price target of $22.00 from 7 analysts. The company's expected revenue for the next quarter is $478.45M, and its EPS for the previous quarter was $0.41, with an expectation of $0.59 for the upcoming quarter. Most analysts rate the stock as a "Buy."
Pediatrix Medical Group Inc (MD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pediatrix Medical Group Inc (MD), detailing its financial performance by business segment for FY2024, FY2023, FY2022, FY2021, FY2020, and FY2019. The two main segments are Neonatology and other pediatric subspecialties, and Maternal-fetal medicine. The data shows that neonatology and other pediatric subspecialties account for the majority of the company's revenue.
Pediatrix Medical Group Inc (MD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Pediatrix Medical Group Inc (MD)'s shareholder structure, highlighting major institutional investors and their proportional holdings. It also outlines the distribution of shareholder types and traces institutional shareholding changes over several quarters.
Pediatrix Medical Group Inc (MD) Risk Assessment: Volatility, Financial Risk & Investment Risk
Pediatrix Medical Group Inc (MD) has a current risk assessment score of 5.98, ranking 35 out of 76 in the Healthcare Providers & Services industry. The stock's beta of 0.70 indicates it tends to underperform during market uptrends but experiences smaller declines during downtrends. The U.S. Dollar Index's neutral state has a neutral effect on the domestic-focused industry.
Pediatrix (MD) EVP Mary Ann Moore reports 36,814-share bona fide stock gifts
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported bone fide gifts of 36,814 shares of common stock. These transactions on June 9, 2026, involved transferring 18,407 shares to a family trust and an equal amount from her direct holdings. Following these transfers, Moore directly holds 78,059 shares and indirectly holds 111,831 shares through the trust, with her beneficial interest limited to her pecuniary stake.
Pediatrix Medical Group (MD) Stock Analysis Report | Ratings, Financials & Performance
This report provides a comprehensive analysis of Pediatrix Medical Group (MD) stock, covering its ratings, financial health, and performance. It details the company's physician services, growth, value, momentum, and quality scores, along with a three-year earnings history and financial statements. The analysis also compares Pediatrix to its peers and evaluates its past performance using the Sharpe ratio.
MD - Pediatrix Medical Group Inc Stock Price and Quote
This article provides a comprehensive overview of Pediatrix Medical Group Inc (MD) stock, including its latest stock price, financial statistics, analyst ratings, and recent news. It details key financial metrics, performance indicators, insider transactions, and a list of historical analyst actions and company news releases.
Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
Pediatrix Medical Group has published new research in the Journal of Perinatology concerning probiotic use and necrotizing enterocolitis (NEC) in preterm infants. The study, utilizing data from the Pediatrix Clinical Data Warehouse, found that NEC rates rose in hospitals that reduced probiotic use after a 2023 FDA warning. The findings suggest that abrupt discontinuation of probiotics may have had unintended harmful consequences, and underscore the need for further prospective clinical trials.
Pediatrix (MD) CFO receives 31,800 restricted shares with multi-year vesting
Pediatrix Medical Group's EVP, CFO, and Treasurer, Kasandra H. Rossi, was granted 31,800 restricted shares of common stock as an annual equity award. These shares will vest over several years, with 25% vesting on June 1, 2027, 25% on June 1, 2028, and the remaining 50% on June 1, 2029. In connection with previous awards, 3,701 restricted shares were withheld for tax purposes, bringing Rossi's direct holdings to 105,100 common shares.
Pediatrix (MD) EVP uses 11,944 vested shares to cover tax withholding
Pediatrix Medical Group's EVP, Mary Ann E. Moore, reported a routine tax-withholding disposition where 11,944 common shares, valued at $21.54 per share, were withheld to cover tax obligations upon the vesting of restricted stock. Following this transaction, Moore directly holds 96,466 common shares. Additionally, a trust where she and her spouse are trustees indirectly holds 93,424 common shares.
Pediatrix (MD) CEO reshapes restricted stock awards while retaining 313,710 shares
Pediatrix Medical Group CEO Mark S. Ordan has adjusted his equity compensation, receiving 127,198 restricted shares and having 19,119 shares withheld for taxes. An earlier 2025 award was also revised due to plan limitations, with 97,174 shares re-granted. Following these transactions, Ordan directly holds 313,710 shares of Pediatrix common stock.
Pediatrix Medical Group Study Evaluates NICU Protocols for Respiratory, Nutritional, and Infection Management
Pediatrix Medical Group researchers have published a new study analyzing diagnostic and treatment protocols in neonatal intensive care units (NICUs) to enhance outcomes for premature and critically ill infants. The research evaluates existing neonatal interventions across multiple clinical sites, focusing on respiratory support, nutritional management, and infection prevention. Findings aim to help medical professionals refine care strategies and improve stabilization and long-term development for high-risk newborns.
Q1 Earnings Roundup: Pediatrix Medical Group (NYSE:MD) And The Rest Of The Healthcare Providers & Services Segment
This article provides a Q1 earnings roundup for the healthcare providers & services segment, focusing on Pediatrix Medical Group (NYSE:MD) and highlighting other key performers. It details the financial results of Pediatrix Medical Group, agilon health (NYSE:AGL), Option Care Health (NASDAQ:OPCH), McKesson (NYSE:MCK), and LifeStance Health Group (NASDAQ:LFST), indicating both strong and weak performances within the sector. The piece also briefly touches upon market shifts from AI concerns to geopolitical risks in late 2025 and early 2026.
Assessing Pediatrix Medical Group (MD) Valuation As Shares Show Mixed Short Term Momentum
Pediatrix Medical Group (MD) is showing mixed short-term stock performance, with a 5.3% drop in the last month but a 9.1% gain over three months. The stock is currently trading at $21.54, which is about 63% below one intrinsic value estimate. While a narrative model suggests the stock is fairly valued at $21.33, a Discounted Cash Flow model indicates a much higher potential value of $58.65, presenting conflicting signals for investors to consider.
A Look At Pediatrix Medical Group (MD) Valuation After Q1 Update And Raised Analyst Outlook
Pediatrix Medical Group (MD) is under scrutiny after its Q1 update, which showed improved profitability and reaffirmed 2026 EBITDA guidance. While a widely followed narrative suggests the stock is 7.9% overvalued compared to its fair value of $21.33, Simply Wall St's DCF model indicates a significant undervaluation with a potential future cash flow value of $59.26 per share. The article highlights mixed sentiment surrounding MD, prompting investors to consider operational improvements against future growth assumptions.
Here's why Pediatrix Medical Group (MD) is a strong growth stock
This article from MSN suggests that Pediatrix Medical Group (MD) is a strong growth stock. It does not provide further details or analysis within the given content.
MD SEC Filings - Pediatrix Medical Group, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pediatrix Medical Group (Ticker: MD) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material events, and insider trading forms. It lists recent filings from August and July 2025, detailing their nature (e.g., insider trading, quarterly earnings, material events) and their Rhea-AI Impact and Sentiment. The page also offers FAQs about the number and recency of filings, along with various financial rankings and stock data for Pediatrix Medical Group.
Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
Pediatrix Medical Group (MD) reported strong Q1 2026 earnings, beating Zacks Consensus Estimates for both earnings per share and revenue. The company posted earnings of $0.44 per share against an estimated $0.37, and revenues of $476.2 million, surpassing the $467.05 million estimate. Despite outperforming expectations, the stock has slightly underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold).
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Pediatrix Medical (MD) is positioned for growth due to strong cash collections, a favorable payer mix, higher patient acuity in neonatology, and strategic acquisitions. The company's shares have risen 9.7% year-to-date, contrasting with an industry decline. Despite its potential
Weis family trust tied to Pediatrix (MD) director sells 36,028 shares
A trust associated with Pediatrix Medical Group director Shirley A. Weis sold 36,028 shares of common stock in an open-market transaction for a weighted average price of $23.75 per share, totaling approximately $855,665. The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees, now holds no Pediatrix shares, though Shirley A. Weis directly retains 18,623 shares. This sale is likely to be viewed as a negative signal given the insider selling activity.
Pediatrix (NYSE: MD) director McEachin reports 22,854-share stock gift
Pediatrix Medical Group (NYSE: MD) director Thomas McEachin reported two bona fide gifts totaling 22,854 shares of company common stock on May 13, 2026. These non-cash charitable-style transfers included one gift of 11,427 shares to a trust where he and his spouse are trustees and beneficiaries, and another 11,427 shares from directly held stock. Following these transactions, McEachin indirectly owns 66,073 shares through the trust and directly owns 7,196 shares.
Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?
Pediatrix Medical Group (MD) reported strong first-quarter 2026 results, surpassing EPS expectations and reaffirming its full-year adjusted EBITDA outlook of US$280 million to US$300 million. This performance, driven by pricing and payer mix despite volume declines, reinforces the company's investment narrative, which hinges on stable demand and resilient cash flows in hospital-based neonatal and maternal care. While the shareholder approval of an expanded incentive compensation plan aims to retain talent, investors should remain cautious about potential future reimbursement and regulatory pressures.
Pediatrix Medical Group (NYSE: MD) files Form 144 to resell 36,028 shares
Pediatrix Medical Group (NYSE: MD) has filed a Form 144 notice through Robert W. Baird & Co. to propose the resale of 36,028 restricted common shares. These shares are tied to compensatory vesting events from 2021, 2023, 2024, and 2025. A Form 144 permits a holder to comply with resale conditions, but the filing itself does not confirm that the shares have been sold.
Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?
Pediatrix Medical Group (MD) reported strong first-quarter 2026 results, beating EPS expectations and reaffirming its full-year adjusted EBITDA outlook. This positive performance was driven by pricing and payer mix benefits, despite modest volume declines. The company's investment narrative now hinges on its ability to convert stable demand into resilient cash flows amid potential reimbursement and regulatory pressures.
[Form 4] Pediatrix Medical Group, Inc. Insider Trading Activity
Mary Ann E. Moore, EVP and General Counsel of Pediatrix Medical Group, Inc., reported a gift transfer of 40,826 shares of company stock to a family trust on May 11, 2026. Following this transaction, she directly holds 108,410 shares and indirectly holds 93,424 shares through the trust, disclaiming beneficial interest in the trust-held shares except for her pecuniary interest. This Form 4 filing details the insider trading activity, showing a neutral impact and sentiment according to Rhea-AI.
Pediatrix. (MD) Reports Q1 EPS Beat
Pediatrix Medical Group, Inc. (NYSE:MD) reported stronger-than-expected Q1 2026 results, with adjusted EPS of 44 cents against an estimate of 38 cents, and revenue of $476 million, surpassing the $465.82 million consensus. The company reaffirmed its FY26 adjusted EBITDA outlook of $280M-$300M. Analysts at Jefferies and Truist adjusted their price targets for MD following the positive performance.
Pediatrix (NYSE: MD) director awarded 7,196 restricted shares
Pediatrix Medical Group (NYSE: MD) director Sylvia Jean Young was awarded 7,196 restricted shares of common stock on May 7, 2026, as an annual equity award under the company's 2008 Incentive Compensation Plan. These shares were granted at no cash cost and will vest on May 7, 2027. Following this transaction, Young directly holds 47,814 shares of Pediatrix common stock.
